Whereas most patients maintained humoral immunity throughout the observation period, we observed reduced cellular immune reactivity as measured by the ancestral-strain-stimulated ELISpot assay in a subset of patients. Half of the individuals (50%; 14/28) maintained cellular immunity three months after the fifth dose, despite acquiring humoral immunity.
19,252 Deaths · 90,937 Hospitalizations · 120,007 Urgent Care · 201,607 Doctor Office Visits · 2,552 Anaphylaxis · 6,409 Bell's Palsy · 2,073 Miscarriages · 9,534 Heart Attacks · 28,862 Myocarditis · 18,789 Permanently Disabled · 9,359 Thrombocytopenia · 15,483 Life Threatening · 36,992 Severe Allergic Reaction · 8,264 Shingles · 5,336 Myocarditis/Pericarditis · 3,737 Thrombocytopenia/Low Platelet ·
·
19,252 Deaths · 90,937 Hospitalizations · 120,007 Urgent Care · 201,607 Doctor Office Visits · 2,552 Anaphylaxis · 6,409 Bell's Palsy · 2,073 Miscarriages · 9,534 Heart Attacks · 28,862 Myocarditis · 18,789 Permanently Disabled · 9,359 Thrombocytopenia · 15,483 Life Threatening · 36,992 Severe Allergic Reaction · 8,264 Shingles · 5,336 Myocarditis/Pericarditis · 3,737 Thrombocytopenia/Low Platelet ·
·